You are on page 1of 6
Approach to management of hyperglycemia’ Patient attitude and expected treatment efforts Risks potentially associated with hypoglycemia, other adverse events Disease duration Life expectancy Important comorbidities Established vascular complications Resources, support system More Less _ High motvated, adherent. Less motivated, nonadherent ‘icolont settcare capacllos poor sel-care capectios | High 4 ) Newly diagnosea Tong-stanging | tone ‘Shon | Reaem Few frie ‘Severe | Reson Few Tene ‘Severe | Readily avallaple Limited Table Propane of carrny alae gla cu-overing ago that may guide trast choice nual pane with tp? dhe mle iy rege on comonés)___ cals neh, pee sdnaoes patenogs cat aie rae ae a TGaspntestal ade a tow beds + eloran app “eager Gate 12 No hypogiyoemia ‘© Lactic acidosis risk (rare) hig So oess sen eerie a ab Siete ores Sesion — Gekopdarnct —}hlnnonioa = Eteninepelont = Hyogo bw 74 secine cTitGeectarek Swi et ‘aos Tics peo ens sap, a {lle stsudumby + Glimepiride tow Sepimie Leeminie ramet st pulnemin Lng ce meet ‘a. gins + Reuince lane tractus 2 Nasi rerbones sDoinghenbity 175s Beadle ‘realtone sre Sanya es eee ee ea Prd geese EEESES sa cls tt may ripe Sates Sines HTRDL onto) ime, fin gordon oifbecns esi) (PONSIE, tfc (eee \poatin wGheosidae 6 Acathose Tnbibis mestinal sSlowsyntetna ‘+ No hypoglycemia . Generally modest HbA ‘Moderae ae Spon Ting kobe yume * cba shi Sigsidaibiopin * HERR inl ade eee seen rears (SEES) stage sepa sneneent (DeP4 inhibkors ¢ Siagliptin Inhibus DPP-4acwvay, 6] Insulin secretion ‘+ No hypoglycemia igh ¢ Vildaghipuint ‘nemseing postprandial t) Well tolerated 0 Soest «4 age eh ee Gpemcamaoa “ Gudiedsenon “able 1 Contimed am comin erimags cat Beals Cateren “eagle tans Fh \oncmee =) sconpcen cr pon lh Tei ate — co tense quel? PA seepor Eyermide apnissSFaenatde release sugjnie Aesslamemaic* «Pride! er ‘etna ies 1 Taso seretion ‘= Nohypagyemia (Glucesecependem) —Waight edacton +1 Glusgon wereton 11 Foteal lor (Glucesedependen) Teprosed fecll «Sloe gas eying mabetinetion Tt Sitety +1 Cardlonseaar (protective ations + L.Gheagen eton——_« L Rosina ge {Slows gave empeying octsion Tt sitety = Weght redaction #1 Grose dispos + Unverslyefectve U1 Mepategcos 2 Treeretcly unlined erat g vay 2 | Misoescula nk UKEDS) + Geneallymodes ThA. igh linac) Dizsinestsrncope Fatigue av sGasoesina aes ‘eanevtorainy) 1a peat nd * pyro iors ae jectable 1 Tetnng regi ments ‘Generllymodest Yas. ih fica) 4 Tiaining requirements “Suga or pauens) b> Initial drug monotherapy Effcay (HA) ypoglycama Sie flocs Two-crug combinations? cacy dL) Hypostyeoma Hsjor eco steaie Cone Three-drug combinations More complex insulin strategies ‘Metformin tiah ew a teams Bite H pec resented ion ater naps oc red owt eortaton arora Tere reo Watarn Sulforyiree™| nih ‘roderte ak ee Iroacadteeachincitloe bre afer = mothe, poten tending cainaton Tater Teton Natio aor Tatem Suter Pap ona ™ + basa) saute 7m “ I cana bere tat lace bn Il as ale ace HAT arte: 38 meh ata more egacrauin sratgy”waly in contami ona ors named Insuline (multiple daily doses) Algoritme Pengelolaan DM tipe-2 Tanpa Dekompensasi Tar Th Tom + monoterapi = gaye hidup sehat Dinayataken gagal bila ‘terapl selama 2-3 ulan ada tap tahap tidak mencapat target terapt GHS HbALC

You might also like